<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation of hibernating myocardium</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation of hibernating myocardium</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation of hibernating myocardium</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Wilson S Colucci, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeroen J Bax, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>It has become apparent that impaired left ventricular (LV) function in patients with coronary heart disease (CHD) is not always an irreversible process, but may be the result of stunned or hibernating myocardium:</p><p class="bulletIndent1"><span class="glyph">●</span>Transient postischemic dysfunction is called "stunned" myocardium</p><p class="bulletIndent1"><span class="glyph">●</span>Chronic but potentially reversible ischemic dysfunction due to a stenosed coronary artery is called "hibernating" myocardium</p><p></p><p>From 20 to more than 50 percent of patients with chronic ischemic LV dysfunction have a significant amount of viable hibernating myocardium and, therefore, the potential for clinically important improvement in LV function after revascularization  (<a class="graphic graphic_figure graphicRef55621" href="/d/graphic/55621.html" rel="external">figure 1</a>) [<a href="#rid1">1-4</a>]. (See  <a class="medical medical_review" href="/d/html/1507.html" rel="external">"Treatment of ischemic cardiomyopathy"</a>.)</p><p>The approach to the detection of hibernating myocardium will be reviewed here  (<a class="graphic graphic_table graphicRef59009" href="/d/graphic/59009.html" rel="external">table 1</a>). The pathophysiology of and clinical syndromes associated with hibernation are discussed separately. (See  <a class="medical medical_review" href="/d/html/1516.html" rel="external">"Pathophysiology of stunned or hibernating myocardium"</a> and  <a class="medical medical_review" href="/d/html/1527.html" rel="external">"Clinical syndromes of stunned or hibernating myocardium"</a> and  <a class="medical medical_review" href="/d/html/1507.html" rel="external">"Treatment of ischemic cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H2887910469"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>Ischemic cardiomyopathy is defined as myocardial dysfunction (with reduced LV systolic function) with resultant heart failure (HF) symptoms that are a direct result of coronary artery disease (CAD) [<a href="#rid5">5</a>]. Patients with ischemic cardiomyopathy may have scarring from one or more prior myocardial infarctions (MI), viable but hibernating myocardium resulting from chronic myocardial ischemia, or a combination of the two.</p><p>Hibernating myocardium is defined as a region of depressed myocardial contractility at rest due to persistently impaired coronary blood flow [<a href="#rid6">6-9</a>]. It may be present in chronic stable or unstable angina, acute MI, HF with or without severe LV systolic dysfunction, and an anomalous coronary artery. (See  <a class="medical medical_review" href="/d/html/1527.html" rel="external">"Clinical syndromes of stunned or hibernating myocardium"</a>.)</p><p>Since the ischemic myocardium remains viable, the LV dysfunction can be partially or completely restored to normal by improving blood flow or by reducing oxygen demand. Both the reduction in resting coronary blood flow in hibernating segments and the improvement following percutaneous coronary intervention have been directly demonstrated by cardiovascular magnetic resonance (CMR) imaging [<a href="#rid10">10</a>].</p><p>Positron emission tomography (PET) has shown that regions with abnormal wall motion may still be metabolically active; these are the regions that can improve after revascularization [<a href="#rid11">11</a>]. In an autopsy series, 52 percent of myocardial segments that were hypokinetic had normal myocardium when examined histologically, compared with only 7 percent of akinetic or dyskinetic segments [<a href="#rid12">12</a>].</p><p>Hibernating myocardium has been thought to be different from stunned myocardium in which myocardial dysfunction persists for a variable period after transient myocardial ischemia. However, several observations suggest that the difference between hibernation and stunning may be one of degree: in hibernation, resting blood flow is low, whereas in stunning, resting flow is normal but maximal blood flow is reduced, leading to the hypothesis that hibernation may result in some cases from repetitive stunning, secondary to repeated episodes of ischemia, or from chronic stunning  (<a class="graphic graphic_figure graphicRef62157" href="/d/graphic/62157.html" rel="external">figure 2</a>) [<a href="#rid13">13</a>]. Hibernation has more damage than stunned myocardium; recovery may thus also take longer after revascularization [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/1516.html" rel="external">"Pathophysiology of stunned or hibernating myocardium", section on 'Relation between hibernation and stunning'</a>.)</p><p class="headingAnchor" id="H2060595936"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The presence of ischemic cardiomyopathy is an independent predictor of mortality; in addition, the extent of CAD as determined by angiography contributes more prognostic information than the clinical diagnosis of an ischemic cardiomyopathy alone [<a href="#rid15">15</a>]. The diagnostic approach to ischemic cardiomyopathy consists of two steps: the detection of clinically significant CAD and the detection of potentially reversible hibernating (ie, viable) myocardium [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H4063337743"><span class="h2">Detection of coronary disease</span><span class="headingEndMark"> — </span>Because of the frequency of ischemic heart disease as a cause of HF and the observation that it also accounts for some cases of initially unexplained HF [<a href="#rid17">17</a>], evaluation for CAD is usually part of the evaluation of patients with newly diagnosed HF. This issue is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/3485.html" rel="external">"Determining the etiology and severity of heart failure or cardiomyopathy", section on 'Detection of coronary artery disease'</a>.)</p><p>Summarized briefly, chest pain alone is not sufficient to make the diagnosis, since up to one-third of patients with nonischemic cardiomyopathy have chest pain that may resemble angina or be atypical. The evaluation for CAD typically consists of exercise stress testing, often with some form of myocardial imaging, which can detect ischemia and provides prognostic information by assessment of exercise capacity, and/or coronary arteriography.</p><p>The 2013 American College of Cardiology Foundation/American Heart Association guidelines on HF recommended that cardiac catheterization with coronary angiography is reasonable in patients with new onset HF of uncertain cause who would be eligible for revascularization [<a href="#rid18">18</a>]. In addition, noninvasive imaging to detect myocardial ischemia and viability was considered reasonable in patients with new onset HF who are known to have CAD but no angina, again assuming that the patient is eligible for revascularization.</p><p>It is essential that the angiographic findings be considered in the context of the patient's history and other data. As mentioned above, the presence of asymptomatic angiographic CAD in patients with dilated cardiomyopathy does not prove causality unless there is evidence of prior infarction or hibernating myocardium [<a href="#rid19">19,20</a>]. (See <a class="local">'Definition'</a> above.)</p><p>Although scintigraphic and echocardiographic techniques have traditionally been the noninvasive ischemia tests of choice, noninvasive coronary arteriography, including the use of multidetector row or electron beam computed tomography (CT) and CMR are also being evaluated. The options include CT or CMR angiography and detection of coronary artery calcification by CT or late gadolinium enhancement by CMR. (See  <a class="medical medical_review" href="/d/html/5308.html" rel="external">"Cardiac imaging with computed tomography and magnetic resonance in the adult"</a> and  <a class="medical medical_review" href="/d/html/5297.html" rel="external">"Coronary artery calcium scoring (CAC): Overview and clinical utilization"</a> and  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Cardiomyopathy'</a>.)</p><p class="headingAnchor" id="H423460386"><span class="h2">Detection of viable (hibernating) myocardium</span><span class="headingEndMark"> — </span>Unless the patient is not a candidate for revascularization of any kind, noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients with known CAD and no angina [<a href="#rid18">18</a>]. The guidelines also noted that, although the efficacy is less well established, noninvasive imaging may be considered to define the likelihood of CAD in other patients with HF and LV dysfunction. The efficacy of the methods used to detect regions of viable myocardium in which function might improve after revascularization is discussed in detail below. (See <a class="local">'Efficacy of imaging tests'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">EFFICACY OF IMAGING TESTS</span><span class="headingEndMark"> — </span>Several tests can assist in the evaluation of myocardial viability and contractile reserve and identification of patients in whom there is the potential for recovery of LV function with revascularization. These tests include radionuclide myocardial perfusion imaging (rMPI), <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography, positron emission tomography (PET) scanning, and an increase in segmental contraction with pharmacologic or nonpharmacologic stimulation (postextrasystolic potentiation) during left ventriculography.</p><p>Computed tomography (CT) and CMR also can detect hibernating myocardium, but their roles have not been systematically evaluated and comparisons with rMPI are limited. (See  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Radionuclide myocardial perfusion imaging</span><span class="headingEndMark"> — </span>Noninvasive testing with thallium or technetium sestamibi rMPI or PET is often performed to identify the presence of dysfunctional segments that are viable. The major rMPI techniques are thallium stress-redistribution-reinjection single photon emission computed tomography (SPECT), thallium rest-redistribution SPECT, and technetium-sestamibi SPECT. PET with the use of tracers to detect myocardial metabolism is an alternative method. The role of myocardial imaging in the detection of myocardial viability is discussed in detail elsewhere and the relative efficacy of the different tests is reviewed below. (See <a class="local">'Pooled analysis of rMPI and DE studies'</a> below and  <a class="medical medical_review" href="/d/html/1473.html" rel="external">"Assessment of myocardial viability by nuclear imaging in coronary heart disease"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Echocardiography</span></p><p class="headingAnchor" id="H9"><span class="h3">End-diastolic wall thickness</span><span class="headingEndMark"> — </span>Since myocardial necrosis is associated with thinning of the myocardial wall, preserved end-diastolic wall thickness may provide a simple method for determining myocardial viability. This was investigated in a study that compared the end-diastolic wall thickness, obtained on a resting two-dimensional echocardiography, with the results of <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> stress echocardiography (DSE) and rest-distribution <a class="drug drug_general" data-topicid="101540" href="/d/drug information/101540.html" rel="external">thallium-201</a> scan [<a href="#rid21">21</a>]. An end-diastolic wall thickness ≤0.6 cm excluded the potential for functional recovery with a sensitivity and specificity of 94 and 48 percent, respectively, which was similar to the results with thallium scanning. Combination of the end-diastolic wall thickness with the results of DSE had a sensitivity and specificity of 88 and 77 percent.</p><p>However, the presence of a thinned wall does not exclude the possibility of myocardial viability. (See <a class="local">'Magnetic resonance imaging'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h3">Dobutamine echocardiography</span><span class="headingEndMark"> — </span>DSE is an important noninvasive clinical tool for the detection of hibernating myocardium  (<a class="graphic graphic_figure graphicRef61817" href="/d/graphic/61817.html" rel="external">figure 3</a> and <a class="graphic graphic_figure graphicRef55003" href="/d/graphic/55003.html" rel="external">figure 4</a>) [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/d/html/1528.html" rel="external">"Dobutamine stress echocardiography in the evaluation of hibernating myocardium"</a>.)</p><p><a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">Dobutamine</a> echocardiography examines the "inotropic reserve" of dysfunctional but viable myocardium.</p><p>Viable myocardium shows improved regional contractile function (inotropic reserve), as assessed by simultaneous transthoracic echocardiography, in response to these agents. The prevalence of contractile reserve in patients with CHD and LV dysfunction is independent of the angiographic extent and severity of coronary disease [<a href="#rid24">24</a>] and the improvement in contractility in hypoperfused viable myocardium does not require an increase in regional myocardial perfusion [<a href="#rid25">25</a>] although <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> may also increase myocardial blood flow [<a href="#rid26">26</a>].</p><p>A contractile response to <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> appears to require at least 50 percent viable myocytes in a given segment and correlates inversely with the extent of interstitial fibrosis on myocardial biopsy [<a href="#rid27">27</a>]. In comparison, rMPI can identify segments with fewer viable myocytes. In one series, for example, dobutamine echocardiography and thallium imaging showed equivalent sensitivity among segments with more than 75 percent viable myocytes (78 versus 87 percent) but dobutamine was much less sensitive among segments with 25 to 50 percent viable myocytes (15 versus 82 percent) [<a href="#rid28">28</a>].</p><p><a class="drug drug_general" data-topicid="8983" href="/d/drug information/8983.html" rel="external">Atropine</a> may be given with <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> to enhance the diagnostic value of the technique by increasing myocardial blood flow; in one series, atropine was necessary in 36 percent of patients to evaluate myocardial viability [<a href="#rid29">29</a>]. In addition to atropine therapy, other methods to improve the predictive value are to combine dobutamine echocardiography with myocardial contrast echocardiography (MCE) [<a href="#rid30">30</a>], Doppler assessment of mitral inflow pattern [<a href="#rid31">31</a>], and strain rate imaging (SRI) with tissue Doppler [<a href="#rid32">32,33</a>].</p><p>Another possible approach is <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> given with <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a>. Potential efficacy was illustrated in a report of 32 patients in whom 309 of 512 myocardial segments were akinetic or dyskinetic. In terms of improved contractility after revascularization, nitroglycerin-dobutamine echocardiography had a lower sensitivity than rest-redistribution thallium and MCE (63 versus 95 and 87 percent, respectively), but was the most specific (83 versus 37 and 48 percent) [<a href="#rid34">34</a>]. Nitroglycerin alone increased regional thickening in 20 percent of viable akinetic segments, suggesting that it may be a useful addition to dobutamine stimulation.</p><p class="headingAnchor" id="H11"><span class="h3">TDE/strain rate imaging</span><span class="headingEndMark"> — </span>A refinement in the assessment of regional LV function has been SRI from tissue Doppler echocardiography (TDE). SRI involves mathematical subtraction of the whole heart or translational motion from regional thickening velocity using a transmural data set from color-coded TDE. The results are less subjective than with wall motion scoring with traditional <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography. (See  <a class="medical medical_review" href="/d/html/5298.html" rel="external">"Tissue Doppler echocardiography", section on 'Strain and strain rate imaging'</a>.)</p><p>When used with low dose <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a>, TDE is a useful method for assessing the degree of myocardial viability [<a href="#rid32">32,33</a>]. The possible incremental value SRI to wall motion scoring was illustrated in review of 55 stable patients with a prior myocardial infarction (MI) and mean LVEF of 36 percent [<a href="#rid33">33</a>]. The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>Global functional recovery was seen after CABG in 21 patients (mean LVEF 35 percent at baseline to 47 percent at follow-up). There remaining patients had no increase in LVEF after CABG (38 to 39 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The combination of SRI and wall motion scoring significantly increased the sensitivity for predicting recovery of function after CABG compared with wall motion scoring alone (82 versus 73 percent).</p><p></p><p class="headingAnchor" id="H12"><span class="h3">Mitral inflow pattern</span><span class="headingEndMark"> — </span>Limited data indicate that the early diastolic deceleration time may correlate with the extent of myocardial viability. The value of measuring the early diastolic deceleration time (DT) on Doppler was assessed in 40 patients with ischemic cardiomyopathy who also underwent <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography and rMPI [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/d/html/5304.html" rel="external">"Echocardiographic evaluation of left ventricular diastolic function in adults"</a>.)</p><p>The following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>There was a linear relationship between DT and both the number of viable segments on <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography and the increase in LVEF after CABG surgery.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A DT &gt;150 msec predicted an increase in LVEF after CABG of ≥5 percent (mean 29 percent at baseline to 40 percent after surgery) with a sensitivity and specificity of about 80 percent. In comparison, a DT ≤150 msec predicted an increase in LVEF &lt;5 percent (mean 27 percent before and after CABG).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At one year, the rate of death or heart transplantation was much lower in the patients with a DT &gt;150 msec (5 versus 37 percent).</p><p></p><p class="headingAnchor" id="H13"><span class="h2">Pooled analysis of rMPI and DE studies</span><span class="headingEndMark"> — </span>The relative predictive value of the different forms of rMPI and of <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography for detecting hibernating myocardium was evaluated in an analysis from 52 published studies that utilized thallium stress-redistribution-reinjection SPECT, thallium rest-redistribution SPECT, fludeoxyglucose (FDG)-PET scanning, technetium-sestamibi SPECT, or low dose dobutamine echocardiography [<a href="#rid35">35,36</a>]. The following findings were noted  (<a class="graphic graphic_figure graphicRef50864" href="/d/graphic/50864.html" rel="external">figure 5</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For each technique, the negative predictive value was higher than the positive predictive value. The highest negative predictive values were seen with FDG-PET, reinjection thallium SPECT, and <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography, while lower values were noted for rest-redistribution thallium SPECT and technetium-sestamibi SPECT.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The highest positive predictive value was seen with <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography, with intermediate values for FDG-PET, rest-redistribution thallium SPECT, and technetium-sestamibi SPECT, and the lowest value for reinjection thallium SPECT.</p><p></p><p>Most of these studies did not compare imaging techniques in the same patients. In a subset of studies in which two techniques were compared to detect viability, the pooled results showed that <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography had significantly higher positive predictive value than nuclear imaging (84 versus 75 percent) and a significantly lower negative predictive value (69 versus 80 percent).</p><p>Data were also available on the relationship between the change in LVEF after revascularization and the presence or absence of hibernating myocardium on imaging [<a href="#rid35">35,36</a>]. There was a mean increase in LVEF of about 8 percent after revascularization when hibernating myocardium was present (37 versus 45 percent) compared with no change in the absence of hibernation (36 versus 37 percent). The pooled results suggested that <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography had a slightly higher positive and negative predictive values than nuclear imaging (77 versus 70 percent and 85 versus 78 percent, respectively) [<a href="#rid35">35</a>]. (See  <a class="medical medical_review" href="/d/html/1507.html" rel="external">"Treatment of ischemic cardiomyopathy", section on 'Additional imaging'</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Magnetic resonance imaging</span></p><p class="headingAnchor" id="H15"><span class="h3">Wall thickness</span><span class="headingEndMark"> — </span>As with echocardiography, CMR evidence of reduced end-diastolic wall thickness (thinned wall) has been proposed as an indicator of lack of viability. In a study of 35 patients with prior MI and regional akinesia or dyskinesia, resting end-diastolic wall thickness and low dose dobutamine-induced systolic wall thickening were assessed by CMR [<a href="#rid37">37</a>]. Dobutamine-induced wall thickening was a better predictor of residual metabolic activity on PET (sensitivity 81 percent specificity 95 percent) than end-diastolic wall thickness (sensitivity 72 percent and specificity 89 percent). If at least one CMR parameter was used to identify viability, the sensitivity was 88 percent and specificity was 87 percent.</p><p>However, a region of thinned myocardium may be viable with potential for structural and functional recovery following revascularization [<a href="#rid38">38</a>]. Also, normal ventricles have significant regional variation in viable myocardial thickness. Therefore, identification of the extent of scar (eg, through contrast enhancement) along with the extent of viable tissue may provide a more accurate means of evaluating viability.</p><p class="headingAnchor" id="H16"><span class="h3">Contrast-enhanced imaging</span><span class="headingEndMark"> — </span>Contrast-enhanced CMR imaging can be used to identify the extent of myocardial viability. Regions of myocardium exhibiting late (or delayed) gadolinium enhancement (LGE) coincide with regions of myocardial necrosis and irreversible injury; regions that fail to hyperenhance are viable. In addition, quantitative perfusion assessment can document the reduction in resting coronary blood flow in hibernating segments [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Myocardial viability'</a>.)</p><p>In one series of 24 patients with stable CAD and LV dysfunction, delayed (3 to 15 minute) enhancement of contrast-enhanced CMR images were associated with nonviability as established with rest-distribution thallium imaging and <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography [<a href="#rid39">39</a>]. The absence of enhancement correlated with radionuclide and echocardiographic viability, regardless of the status of resting contractile function.</p><p>The degree of enhancement with contrast-enhanced CMR can predict recovery of LV function after revascularization [<a href="#rid40">40,41</a>]. This was illustrated in a study of 50 patients with CAD who had LV dysfunction prior to surgical or percutaneous revascularization; 33 percent of myocardial segments in 80 percent of patients had late myocardial enhancement; 38 percent of segments had abnormal contractility [<a href="#rid40">40</a>]. After revascularization, more dysfunctional segments without enhancement improved (78 versus 17 percent with enhancement of &gt;75 percent of the tissue).</p><p>The likelihood of improvement in regional contractility after revascularization decreased progressively as the transmural extent of hyperenhancement increased. The percentage of the LV that was dysfunctional and not enhanced was significantly related to the degree of improvement in LVEF.</p><p>A similar relationship was noted in another series [<a href="#rid41">41</a>]. An additional finding was that, among the nonenhancing or minimal enhancing segments that did not improve after revascularization, 36 percent showed new late enhancement on the early postoperative CMR scan.</p><p>Magnetic resonance myocardial tagging is another CMR method that quantifies local myocardial segment shortening throughout the LV myocardium at sites across the LV wall thickness. When combined with low dose <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a>, this method can quantify the amount of myocardial viability, based upon myocardial shortening and thickening, after an acute MI and may provide prognostic information. (See  <a class="medical medical_review" href="/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging", section on 'Myocardial viability'</a>.)</p><p class="headingAnchor" id="H17"><span class="h3">Kidney disease</span><span class="headingEndMark"> — </span>Gadolinium administration during CMR imaging to patients with moderate to severe kidney disease (particularly dialysis patients) has been associated with the often severe syndrome of nephrogenic systemic fibrosis. It is recommended that gadolinium-based imaging be avoided in such patients. This issue, including the definition of patients at risk, is discussed separately. (See  <a class="medical medical_review" href="/d/html/1955.html" rel="external">"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Newer methods</span><span class="headingEndMark"> — </span>Several newer methods may be useful in the evaluation of hibernating myocardium.</p><p class="headingAnchor" id="H19"><span class="h3">Electroanatomic mapping</span><span class="headingEndMark"> — </span>Electroanatomic mapping, which uses low-intensity magnetic field energy to determine the location of sensor-tipped catheter electrodes in the LV, has been widely applied for mapping of arrhythmias. (See  <a class="medical medical_review" href="/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies", section on 'Mapping and ablation'</a>.)</p><p>By simultaneously measuring the electrical data (amplitude of endocardial electrical signals) and mechanical data (regional wall motion reflecting average local shortening) from the myocardium, which correlate inversely with the extent of myocardial ischemia, this technique may also have a role in distinguishing between infarcted and ischemic, but still viable, myocardium  (<a class="graphic graphic_diagnosticimage graphicRef81609 graphicRef57238 graphicRef81092" href="/d/graphic/81609.html" rel="external">image 1A-C</a>) [<a href="#rid42">42-46</a>].</p><p>The sensitivity and specificity for viable myocardium compared with other imaging studies has ranged from 70 to 80 percent [<a href="#rid42">42,44,45</a>]. In one report of 20 patients in whom testing for viability was directly compared with the results of revascularization, the diagnostic performance of electroanatomic mapping was not as good as that of rMPI with PET or SPECT [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H20"><span class="h3">Myocardial contrast echocardiography</span><span class="headingEndMark"> — </span>MCE utilizes intravenous infusion of microbubbles, which have a distinct ultrasonic density from blood or tissue and which can traverse the microvasculature, permitting visualization of myocardial perfusion. This technique compares favorably with other modalities in the detection of hibernating myocardium, although contrast agents have not yet been US Food and Drug Administration (FDA) approved for this purpose.</p><p>The potential value of MCE was illustrated in a study in which 20 patients with coronary disease and ventricular dysfunction underwent MCE, <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography, and rest-redistribution thallium scintigraphy prior to coronary artery bypass grafting (CABG) [<a href="#rid47">47</a>]. Echocardiography was repeated three to four months after surgery. The sensitivity of MCE in detecting segments with recovery of function after surgery was comparable to that of dobutamine echocardiography or thallium scintigraphy (90, 80, and 92 percent, respectively), and the specificity was significantly greater (63, 54, and 45 percent, respectively).</p><p>A second report compared these three approaches in 32 patients in whom 309 of 512 myocardial segments were akinetic or dyskinetic [<a href="#rid34">34</a>]. In terms of predicting functional recovery after revascularization, MCE had the intermediate sensitivity (87 versus 95 and 63 percent with rest-redistribution thallium and nitroglycerin-dobutamine echocardiography) and specificity (48 versus 37 and 83 percent with rest-redistribution thallium and nitroglycerin-dobutamine echocardiography).</p><p class="headingAnchor" id="H380833257"><span class="h2">Ventriculography</span><span class="headingEndMark"> — </span>Ventriculography is the oldest imaging technique and is rarely used clinically today.</p><p>Assessment of regional wall motion by ventriculography, and its improvement with <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> or positive inotropic stimulation has at least two limitations:</p><p class="bulletIndent1"><span class="glyph">●</span>Due to the subjective nature of this evaluation, it may not be accurate [<a href="#rid48">48</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>The technique used to superimpose the end-systolic silhouette on the end-diastolic silhouette may influence the assessment of regional wall motion function [<a href="#rid49">49</a>]</p><p></p><p>Thus, some assessments that regional wall motion function has improved or deteriorated could be erroneous. The finding of improved wall motion function would be accepted more confidently if it were reflected in improved global LV systolic function or LV ejection fraction (LVEF). However, for LVEF to improve, it appears that wall motion function must improve in at least two to three myocardial regions.</p><p class="headingAnchor" id="H3364925491"><span class="h3">Use of nitroglycerin</span><span class="headingEndMark"> — </span>Since the hibernating myocardium is a result of reduced myocardial blood flow, one way to demonstrate its presence would be to show an improvement in function after reducing the myocardial oxygen requirement with nitrates [<a href="#rid50">50,51</a>]. <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">Nitroglycerin</a> and/ or <a class="drug drug_general" data-topicid="8580" href="/d/drug information/8580.html" rel="external">isosorbide dinitrate</a> with contrast medium, two dimensional echocardiography, or radionuclide ventriculography can be utilized for this purpose. The sensitivity, specificity, and predictive accuracy of nitroglycerin contrast ventriculography for the detection of hibernating myocardium is only 76 percent, 65 percent, and 70 percent, respectively. However, if LV wall segments improve with nitroglycerin preoperatively, there is an 85 percent chance of their improving with coronary artery bypass grafting (CABG) [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H2862531467"><span class="h3">Inotropic stimulation/postextrasystolic potentiation</span><span class="headingEndMark"> — </span>With inotropic stimulation caused by low-dose <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> or postextrasystolic potentiation, the ventriculogram may appear to show an improvement in akinetic wall motion segments by increasing the force of contraction of the normal myocardium leading to a tethering effect on the akinetic segment.</p><p>Despite this limitation, inotropic stimuli may demonstrate reversible abnormal wall motion, a response that appears to be similar to that seen with <a class="drug drug_general" data-topicid="9706" href="/d/drug information/9706.html" rel="external">nitroglycerin</a> [<a href="#rid51">51</a>]. As an example, one study found that low-dose <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> left ventriculography is a useful technique for identifying myocardial viability, especially in patients with a suboptimal dobutamine echocardiographic study [<a href="#rid53">53</a>]. A positive response to inotropic stimuli predicts a better short-and long-term survival with CABG [<a href="#rid54">54-56</a>].</p><p>In patients with global LV dysfunction due to an ischemic cardiomyopathy, improvement in global LV function or LVEF with <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> may be of greater importance than reversibility of a regional wall motion abnormality. In one study of 56 patients with an ischemic cardiomyopathy and multivessel coronary disease, a dobutamine radionuclide ventriculogram, which provides an objective quantification of LV function, was performed to assess viability; a 10 percent increase in global LVEF with low dose dobutamine had a sensitivity, specificity, and positive and negative predictive values of 67, 93, 91, and 72 percent, respectively, for improvement in LV function after CABG [<a href="#rid57">57</a>].</p><p>Concern about the augmentation of myocardial oxygen demand with <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> infusion has led to the evaluation of inamrinone (formerly known as amrinone), an inotropic agent which does not significantly increase oxygen demand because it also induces coronary vasodilation. One study evaluated 44 patients with coronary disease and an LVEF below 40 percent; inamrinone was infused at a dose of 1 mg/kg body weight and LVEF measured with radionuclide ventriculography [<a href="#rid58">58</a>]. An increase in LVEF of ≥10 percent with inamrinone predicted the same increase in LVEF after CABG, while those with a lesser change with inamrinone had little, if any, improvement after CABG [<a href="#rid58">58</a>].</p><p>Increased inotropy can also be observed on ventriculography or echocardiography by measuring the change in LVEF following an induced or spontaneous premature beat (ie, the degree of postextrasystolic potentiation) [<a href="#rid59">59</a>].</p><p class="headingAnchor" id="H21"><span class="h1">RECOMMENDED APPROACH</span><span class="headingEndMark"> — </span>The major imaging tests used to detect hibernating myocardium include thallium stress-redistribution-reinjection, thallium rest-redistribution, positron emission tomography (PET) scanning, technetium sestamibi imaging, and low dose <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography. All of these tests are highly sensitive and can predict the benefit from revascularization, although there are some differences  (<a class="graphic graphic_figure graphicRef50864" href="/d/graphic/50864.html" rel="external">figure 5</a>) [<a href="#rid1">1,35,36,60</a>]. (See <a class="local">'Pooled analysis of rMPI and DE studies'</a> above.)</p><p>We agree with the following conclusions from a Study Group of the European Society of Cardiology [<a href="#rid36">36</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Assessment for hibernation is most relevant in patients with dyspnea rather than angina.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Radionuclide myocardial perfusion imaging (rMPI) and <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography have similar test performance for the detection of viable myocardium. Thus, the choice may depend upon availability, local expertise, and whether a more sensitive (rMPI) or a more specific technique (dobutamine echocardiography) is required for predicting recovery of LV function.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PET scanning or CMR imaging is usually performed if clarification is required after echocardiography and/or rMPI. However, if readily available, PET scanning is an alternative initial test and CMR is an acceptable alternative to echocardiography when assessment of LV function at rest and during stress is also desired.</p><p></p><p>The American College of Cardiography/American Heart Association guidelines on chronic HF reached the following conclusions on noninvasive imaging, unless the patient is not eligible for revascularization of any kind [<a href="#rid18">18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Noninvasive imaging to detect myocardial ischemia and viability is reasonable in patients with known CAD and no angina.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Noninvasive imaging may be considered (evidence less well established) to define the likelihood of CAD in patients with HF and LV dysfunction.</p><p></p><p class="headingAnchor" id="H22"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The detection of viable myocardium is of importance because the restoration of blood flow with revascularization can reverse depressed LV contractility, improve LV function, and reduce long-term mortality, although the latter has not been proven. These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1507.html" rel="external">"Treatment of ischemic cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H2641605718"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/115372.html" rel="external">"Society guideline links: Heart failure in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/115939.html" rel="external">"Society guideline links: Chronic coronary syndrome"</a> and  <a class="medical medical_society_guidelines" href="/d/html/119863.html" rel="external">"Society guideline links: Multimodality cardiovascular imaging appropriate use criteria"</a>.)</p><p class="headingAnchor" id="H500617"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hibernating myocardium, defined as a region of depressed myocardial contractility at rest due to persistently impaired coronary blood flow, can occur in a variety of clinical scenarios (eg, chronic stable or unstable angina, acute myocardial infarction [MI], heart failure). Since the ischemic myocardium remains viable, the left ventricular (LV) dysfunction can be partially or completely restored to normal by improving blood flow or by reducing oxygen demand. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Several tests, including radionuclide myocardial perfusion imaging (rMPI), <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography, positron emission tomography (PET) scanning, and cardiovascular magnetic resonance (CMR) imaging, can assist in the evaluation of myocardial viability and contractile reserve and identification of patients in whom there is the potential for recovery of LV function with revascularization. (See <a class="local">'Efficacy of imaging tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our recommended approach to the evaluation of hibernating myocardium is to begin with either rMPI or <a class="drug drug_general" data-topicid="9380" href="/d/drug information/9380.html" rel="external">dobutamine</a> echocardiography depending upon availability and local expertise. PET scanning or CMR imaging are acceptable alternatives which may have greater sensitivity but are more challenging to perform and not as widely available. (See <a class="local">'Recommended approach'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151.</a></li><li><a class="nounderline abstract_t">Bonow RO. The hibernating myocardium: implications for management of congestive heart failure. Am J Cardiol 1995; 75:17A.</a></li><li><a class="nounderline abstract_t">Ragosta M, Beller GA, Watson DD, et al. Quantitative planar rest-redistribution 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993; 87:1630.</a></li><li><a class="nounderline abstract_t">Auerbach MA, Schöder H, Hoh C, et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999; 99:2921.</a></li><li><a class="nounderline abstract_t">Felker GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002; 39:210.</a></li><li><a class="nounderline abstract_t">Braunwald E, Rutherford JD. Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium". J Am Coll Cardiol 1986; 8:1467.</a></li><li><a class="nounderline abstract_t">Rahimtoola SH. From coronary artery disease to heart failure: role of the hibernating myocardium. Am J Cardiol 1995; 75:16E.</a></li><li><a class="nounderline abstract_t">Kloner RA, Przyklenk K. Hibernation and stunning of the myocardium. N Engl J Med 1991; 325:1877.</a></li><li><a class="nounderline abstract_t">Marban E. Myocardial stunning and hibernation. The physiology behind the colloquialisms. Circulation 1991; 83:681.</a></li><li><a class="nounderline abstract_t">Selvanayagam JB, Jerosch-Herold M, Porto I, et al. Resting myocardial blood flow is impaired in hibernating myocardium: a magnetic resonance study of quantitative perfusion assessment. Circulation 2005; 112:3289.</a></li><li><a class="nounderline abstract_t">Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314:884.</a></li><li><a class="nounderline abstract_t">Cabin HS, Clubb KS, Vita N, Zaret BL. Regional dysfunction by equilibrium radionuclide angiocardiography: a clinicopathologic study evaluating the relation of degree of dysfunction to the presence and extent of myocardial infarction. J Am Coll Cardiol 1987; 10:743.</a></li><li><a class="nounderline abstract_t">Vanoverschelde JL, Wijns W, Borgers M, et al. Chronic myocardial hibernation in humans. From bedside to bench. Circulation 1997; 95:1961.</a></li><li><a class="nounderline abstract_t">Bax JJ, Visser FC, Poldermans D, et al. Time course of functional recovery of stunned and hibernating segments after surgical revascularization. Circulation 2001; 104:I314.</a></li><li><a class="nounderline abstract_t">Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30:1002.</a></li><li><a class="nounderline abstract_t">Chareonthaitawee P, Gersh BJ, Araoz PA, Gibbons RJ. Revascularization in severe left ventricular dysfunction: the role of viability testing. J Am Coll Cardiol 2005; 46:567.</a></li><li><a class="nounderline abstract_t">Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342:1077.</a></li><li><a class="nounderline abstract_t">Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62:e147.</a></li><li><a class="nounderline abstract_t">Repetto A, Dal Bello B, Pasotti M, et al. Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander? Eur Heart J 2005; 26:1519.</a></li><li><a class="nounderline abstract_t">Frustaci A, Chimenti C, Maseri A. Global biventricular dysfunction in patients with asymptomatic coronary artery disease may be caused by myocarditis. Circulation 1999; 99:1295.</a></li><li><a class="nounderline abstract_t">Cwajg JM, Cwajg E, Nagueh SF, et al. End-diastolic wall thickness as a predictor of recovery of function in myocardial hibernation: relation to rest-redistribution T1-201 tomography and dobutamine stress echocardiography. J Am Coll Cardiol 2000; 35:1152.</a></li><li><a class="nounderline abstract_t">Beckmann S, Schartl M, Bocksch W, Fleck E. Diagnosis of coronary artery disease and viable myocardium by stress echocardiography. Diagnostic accuracy of different stress modalities. Eur Heart J 1995; 16 Suppl J:10.</a></li><li><a class="nounderline abstract_t">Cheirif J, Murgo JP. Assessment of myocardial viability by dobutamine echocardiography. Coron Artery Dis 1995; 6:600.</a></li><li><a class="nounderline abstract_t">Main ML, Grayburn PA, Landau C, Afridi I. Relation of contractile reserve during low-dose dobutamine echocardiography and angiographic extent and severity of coronary artery disease in the presence of left ventricular dysfunction. Am J Cardiol 1997; 79:1309.</a></li><li><a class="nounderline abstract_t">Barillà F, De Vincentis G, Mangieri E, et al. Recovery of contractility of viable myocardium during inotropic stimulation is not dependent on an increase of myocardial blood flow in the absence of collateral filling. J Am Coll Cardiol 1999; 33:697.</a></li><li><a class="nounderline abstract_t">Krivokapich J, Czernin J, Schelbert HR. Dobutamine positron emission tomography: absolute quantitation of rest and dobutamine myocardial blood flow and correlation with cardiac work and percent diameter stenosis in patients with and without coronary artery disease. J Am Coll Cardiol 1996; 28:565.</a></li><li><a class="nounderline abstract_t">Nagueh SF, Mikati I, Weilbaecher D, et al. Relation of the contractile reserve of hibernating myocardium to myocardial structure in humans. Circulation 1999; 100:490.</a></li><li><a class="nounderline abstract_t">Baumgartner H, Porenta G, Lau YK, et al. Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium-201 SPECT: correlation with histopathology in explanted hearts. J Am Coll Cardiol 1998; 32:1701.</a></li><li><a class="nounderline abstract_t">Poldermans D, Rambaldi R, Bax JJ, et al. Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction. Eur Heart J 1998; 19:1712.</a></li><li><a class="nounderline abstract_t">Meza MF, Ramee S, Collins T, et al. Knowledge of perfusion and contractile reserve improves the predictive value of recovery of regional myocardial function postrevascularization: a study using the combination of myocardial contrast echocardiography and dobutamine echocardiography. Circulation 1997; 96:3459.</a></li><li><a class="nounderline abstract_t">Yong Y, Nagueh SF, Shimoni S, et al. Deceleration time in ischemic cardiomyopathy: relation to echocardiographic and scintigraphic indices of myocardial viability and functional recovery after revascularization. Circulation 2001; 103:1232.</a></li><li><a class="nounderline abstract_t">Hoffmann R, Altiok E, Nowak B, et al. Strain rate measurement by doppler echocardiography allows improved assessment of myocardial viability inpatients with depressed left ventricular function. J Am Coll Cardiol 2002; 39:443.</a></li><li><a class="nounderline abstract_t">Hanekom L, Jenkins C, Jeffries L, et al. Incremental value of strain rate analysis as an adjunct to wall-motion scoring for assessment of myocardial viability by dobutamine echocardiography: a follow-up study after revascularization. Circulation 2005; 112:3892.</a></li><li><a class="nounderline abstract_t">Ling LH, Christian TF, Mulvagh SL, et al. Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 201 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography. Am Heart J 2006; 151:882.</a></li><li><a class="nounderline abstract_t">Bax JJ, Poldermans D, Elhendy A, et al. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001; 26:147.</a></li><li><a class="nounderline abstract_t">Underwood SR, Bax JJ, vom Dahl J, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 2004; 25:815.</a></li><li><a class="nounderline abstract_t">Baer FM, Voth E, Schneider CA, et al. Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation 1995; 91:1006.</a></li><li><a class="nounderline abstract_t">Kim RJ, Shah DJ. Fundamental concepts in myocardial viability assessment revisited: when knowing how much is "alive" is not enough. Heart 2004; 90:137.</a></li><li><a class="nounderline abstract_t">Ramani K, Judd RM, Holly TA, et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation 1998; 98:2687.</a></li><li><a class="nounderline abstract_t">Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343:1445.</a></li><li><a class="nounderline abstract_t">Selvanayagam JB, Kardos A, Francis JM, et al. Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization. Circulation 2004; 110:1535.</a></li><li><a class="nounderline abstract_t">Bøtker HE, Lassen JF, Hermansen F, et al. Electromechanical mapping for detection of myocardial viability in patients with ischemic cardiomyopathy. Circulation 2001; 103:1631.</a></li><li><a class="nounderline abstract_t">Fuchs S, Hendel RC, Baim DS, et al. Comparison of endocardial electromechanical mapping with radionuclide perfusion imaging to assess myocardial viability and severity of myocardial ischemia in angina pectoris. Am J Cardiol 2001; 87:874.</a></li><li><a class="nounderline abstract_t">Koch KC, vom Dahl J, Wenderdel M, et al. Myocardial viability assessment by endocardial electroanatomic mapping: comparison with metabolic imaging and functional recovery after coronary revascularization. J Am Coll Cardiol 2001; 38:91.</a></li><li><a class="nounderline abstract_t">Gyöngyösi M, Sochor H, Khorsand A, et al. Online myocardial viability assessment in the catheterization laboratory via NOGA electroanatomic mapping: Quantitative comparison with thallium-201 uptake. Circulation 2001; 104:1005.</a></li><li><a class="nounderline abstract_t">Wiggers H, Bøtker HE, Søgaard P, et al. Electromechanical mapping versus positron emission tomography and single photon emission computed tomography for the detection of myocardial viability in patients with ischemic cardiomyopathy. J Am Coll Cardiol 2003; 41:843.</a></li><li><a class="nounderline abstract_t">Shimoni S, Frangogiannis NG, Aggeli CJ, et al. Identification of hibernating myocardium with quantitative intravenous myocardial contrast echocardiography: comparison with dobutamine echocardiography and thallium-201 scintigraphy. Circulation 2003; 107:538.</a></li><li><a class="nounderline abstract_t">Chaitman BR, DeMots H, Bristow JD, et al. Objective and subjective analysis of left ventricular angiograms. Circulation 1975; 52:420.</a></li><li><a class="nounderline abstract_t">Chaitman BR, Bristow JD, Rahimtoola SH. Left ventricular wall motion assessed by using fixed external reference systems. Circulation 1973; 48:1043.</a></li><li><a class="nounderline abstract_t">Helfant RH, Pine R, Meister SG, et al. Nitroglycerin to unmask reversible asynergy. Correlation with post coronary bypass ventriculography. Circulation 1974; 50:108.</a></li><li><a class="nounderline abstract_t">Banka VS, Bodenheimer MM, Shah R, Helfant RH. Intervention ventriculography. Comparative value of nitroglycerin, post-extrasystolic potentiation and nitroglycerin plus post-extrasystolic potentiation. Circulation 1976; 53:632.</a></li><li><a class="nounderline abstract_t">Rahimtoola SH. Postoperative exercise response in the evaluation of the physiologic status after coronary bypass surgery. Circulation 1982; 65:106.</a></li><li><a class="nounderline abstract_t">Dalla Vecchia L, Storti T, Cogliati C, et al. Comparison of low-dose dobutamine ventriculography with low-dose dobutamine echocardiography for predicting regional improvement in left ventricular function after coronary artery bypass grafting. Am J Cardiol 2000; 86:371.</a></li><li><a class="nounderline abstract_t">Popio KA, Gorlin R, Bechtel D, Levine JA. Postextrasystolic potentiation as a predictor of potential myocardial viability: preoperative analyses compared with studies after coronary bypass surgery. Am J Cardiol 1977; 39:944.</a></li><li><a class="nounderline abstract_t">Cohn PF, Gorlin R, Herman MV, et al. Relation between contractile reserve and prognosis in patients with coronary artery disease and a depressed ejection fraction. Circulation 1975; 51:414.</a></li><li><a class="nounderline abstract_t">Nesto RW, Cohn LH, Collins JJ Jr, et al. Inotropic contractile reserve: a useful predictor of increased 5 year survival and improved postoperative left ventricular function in patients with coronary artery disease and reduced ejection fraction. Am J Cardiol 1982; 50:39.</a></li><li><a class="nounderline abstract_t">Zafrir N, Vidne B, Sulkes J, Sclarovsky S. Usefulness of dobutamine radionuclide ventriculography for prediction of left ventricular function improvement after coronary artery bypass grafting for ischemic cardiomyopathy. Am J Cardiol 1999; 83:691.</a></li><li><a class="nounderline abstract_t">Perez-Baliño NA, Masoli OH, Meretta AH, et al. Amrinone stimulation test: ability to predict improvement in left ventricular ejection fraction after coronary bypass surgery in patients with poor baseline left ventricular function. J Am Coll Cardiol 1996; 28:1488.</a></li><li><a class="nounderline abstract_t">Scognamiglio R, Fasoli G, Casarotto D, et al. Postextrasystolic potentiation and dobutamine echocardiography in predicting recovery of myocardial function after coronary bypass revascularization. Circulation 1997; 96:816.</a></li><li><a class="nounderline abstract_t">Bax JJ, Wijns W, Cornel JH, et al. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997; 30:1451.</a></li></ol></div><div id="topicVersionRevision">Topic 1474 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11923039" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7840050" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The hibernating myocardium: implications for management of congestive heart failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491019" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Quantitative planar rest-redistribution 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10359737" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11788209" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A standardized definition of ischemic cardiomyopathy for use in clinical research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3782649" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Reversible ischemic left ventricular dysfunction: evidence for the "hibernating myocardium".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7726119" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : From coronary artery disease to heart failure: role of the hibernating myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1961227" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Hibernation and stunning of the myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1991384" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Myocardial stunning and hibernation. The physiology behind the colloquialisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16286587" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Resting myocardial blood flow is impaired in hibernating myocardium: a magnetic resonance study of quantitative perfusion assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3485252" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Reversibility of cardiac wall-motion abnormalities predicted by positron tomography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3655142" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Regional dysfunction by equilibrium radionuclide angiocardiography: a clinicopathologic study evaluating the relation of degree of dysfunction to the presence and extent of myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9107186" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chronic myocardial hibernation in humans. From bedside to bench.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11568075" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Time course of functional recovery of stunned and hibernating segments after surgical revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9316531" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098417" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Revascularization in severe left ventricular dysfunction: the role of viability testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10760308" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23747642" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15917275" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Coronary atherosclerosis in end-stage idiopathic dilated cardiomyopathy: an innocent bystander?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10077512" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Global biventricular dysfunction in patients with asymptomatic coronary artery disease may be caused by myocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10758955" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : End-diastolic wall thickness as a predictor of recovery of function in myocardial hibernation: relation to rest-redistribution T1-201 tomography and dobutamine stress echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8746932" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diagnosis of coronary artery disease and viable myocardium by stress echocardiography. Diagnostic accuracy of different stress modalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8574453" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Assessment of myocardial viability by dobutamine echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9165148" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Relation of contractile reserve during low-dose dobutamine echocardiography and angiographic extent and severity of coronary artery disease in the presence of left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080470" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recovery of contractility of viable myocardium during inotropic stimulation is not dependent on an increase of myocardial blood flow in the absence of collateral filling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8772740" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Dobutamine positron emission tomography: absolute quantitation of rest and dobutamine myocardial blood flow and correlation with cardiac work and percent diameter stenosis in patients with and without coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430762" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Relation of the contractile reserve of hibernating myocardium to myocardial structure in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9822099" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium-201 SPECT: correlation with histopathology in explanted hearts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9857925" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Safety and utility of atropine addition during dobutamine stress echocardiography for the assessment of viable myocardium in patients with severe left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9396442" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Knowledge of perfusion and contractile reserve improves the predictive value of recovery of regional myocardial function postrevascularization: a study using the combination of myocardial contrast echocardiography and dobutamine echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238266" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Deceleration time in ischemic cardiomyopathy: relation to echocardiographic and scintigraphic indices of myocardial viability and functional recovery after revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11823082" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Strain rate measurement by doppler echocardiography allows improved assessment of myocardial viability inpatients with depressed left ventricular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16365209" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Incremental value of strain rate analysis as an adjunct to wall-motion scoring for assessment of myocardial viability by dobutamine echocardiography: a follow-up study after revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16569554" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Determining myocardial viability in chronic ischemic left ventricular dysfunction: a prospective comparison of rest-redistribution thallium 201 single-photon emission computed tomography, nitroglycerin-dobutamine echocardiography, and intracoronary myocardial contrast echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11276916" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15140530" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7850935" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Comparison of low-dose dobutamine-gradient-echo magnetic resonance imaging and positron emission tomography with [18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14729777" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Fundamental concepts in myocardial viability assessment revisited: when knowing how much is "alive" is not enough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9851954" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11078769" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15353496" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Value of delayed-enhancement cardiovascular magnetic resonance imaging in predicting myocardial viability after surgical revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11273989" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Electromechanical mapping for detection of myocardial viability in patients with ischemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11274943" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparison of endocardial electromechanical mapping with radionuclide perfusion imaging to assess myocardial viability and severity of myocardial ischemia in angina pectoris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11451302" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Myocardial viability assessment by endocardial electroanatomic mapping: comparison with metabolic imaging and functional recovery after coronary revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11524393" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Online myocardial viability assessment in the catheterization laboratory via NOGA electroanatomic mapping: Quantitative comparison with thallium-201 uptake.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12628732" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Electromechanical mapping versus positron emission tomography and single photon emission computed tomography for the detection of myocardial viability in patients with ischemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12566363" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Identification of hibernating myocardium with quantitative intravenous myocardial contrast echocardiography: comparison with dobutamine echocardiography and thallium-201 scintigraphy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1157239" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Objective and subjective analysis of left ventricular angiograms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4270891" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Left ventricular wall motion assessed by using fixed external reference systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4209691" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Nitroglycerin to unmask reversible asynergy. Correlation with post coronary bypass ventriculography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1253384" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Intervention ventriculography. Comparative value of nitroglycerin, post-extrasystolic potentiation and nitroglycerin plus post-extrasystolic potentiation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6979424" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Postoperative exercise response in the evaluation of the physiologic status after coronary bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10946026" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of low-dose dobutamine ventriculography with low-dose dobutamine echocardiography for predicting regional improvement in left ventricular function after coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/301350" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Postextrasystolic potentiation as a predictor of potential myocardial viability: preoperative analyses compared with studies after coronary bypass surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1139754" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Relation between contractile reserve and prognosis in patients with coronary artery disease and a depressed ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6979919" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Inotropic contractile reserve: a useful predictor of increased 5 year survival and improved postoperative left ventricular function in patients with coronary artery disease and reduced ejection fraction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10080420" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Usefulness of dobutamine radionuclide ventriculography for prediction of left ventricular function improvement after coronary artery bypass grafting for ischemic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8917262" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Amrinone stimulation test: ability to predict improvement in left ventricular ejection fraction after coronary bypass surgery in patients with poor baseline left ventricular function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9264487" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Postextrasystolic potentiation and dobutamine echocardiography in predicting recovery of myocardial function after coronary bypass revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9362401" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
